CA2214895A1 - Improved pharmaceutical composition comprising fenofibrate - Google Patents

Improved pharmaceutical composition comprising fenofibrate

Info

Publication number
CA2214895A1
CA2214895A1 CA2214895A CA2214895A CA2214895A1 CA 2214895 A1 CA2214895 A1 CA 2214895A1 CA 2214895 A CA2214895 A CA 2214895A CA 2214895 A CA2214895 A CA 2214895A CA 2214895 A1 CA2214895 A1 CA 2214895A1
Authority
CA
Canada
Prior art keywords
fenofibrate
pharmaceutical composition
improved pharmaceutical
improved
making
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA2214895A
Other languages
French (fr)
Other versions
CA2214895C (en
Inventor
Bernard Charles Sherman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to CA002214895A priority Critical patent/CA2214895C/en
Priority to US09/154,521 priority patent/US6444225B1/en
Priority to EP98307588A priority patent/EP0904781A3/en
Priority to JP10264722A priority patent/JPH11152227A/en
Priority to AU86073/98A priority patent/AU731176B2/en
Publication of CA2214895A1 publication Critical patent/CA2214895A1/en
Application granted granted Critical
Publication of CA2214895C publication Critical patent/CA2214895C/en
Priority to US10/189,009 priority patent/US20030031705A1/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Abstract

The bioavailability of fenofibrate is improved by making a solid dispersion of adisentegrant in the fenofibrate. Method of making said solid dispersion comprising melting the fenofibrate, blending the disintegrant into the melt, and resolidifying the mixture.
CA002214895A 1997-09-19 1997-09-19 Improved pharmaceutical composition comprising fenofibrate Expired - Fee Related CA2214895C (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
CA002214895A CA2214895C (en) 1997-09-19 1997-09-19 Improved pharmaceutical composition comprising fenofibrate
US09/154,521 US6444225B1 (en) 1997-09-19 1998-09-16 Pharmaceutical composition comprising fenofibrate
EP98307588A EP0904781A3 (en) 1997-09-19 1998-09-17 Improved pharmaceutical composition comprising fenofibrate
JP10264722A JPH11152227A (en) 1997-09-19 1998-09-18 Improved pharmacological composition comprising fenofibrate
AU86073/98A AU731176B2 (en) 1997-09-19 1998-09-21 Improved pharmaceutical composition comprising Fenofibrate
US10/189,009 US20030031705A1 (en) 1997-09-19 2002-07-05 Pharmaceutical composition comprising fenofibrate

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CA002214895A CA2214895C (en) 1997-09-19 1997-09-19 Improved pharmaceutical composition comprising fenofibrate

Publications (2)

Publication Number Publication Date
CA2214895A1 true CA2214895A1 (en) 1998-11-27
CA2214895C CA2214895C (en) 1999-04-20

Family

ID=4161415

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002214895A Expired - Fee Related CA2214895C (en) 1997-09-19 1997-09-19 Improved pharmaceutical composition comprising fenofibrate

Country Status (5)

Country Link
US (2) US6444225B1 (en)
EP (1) EP0904781A3 (en)
JP (1) JPH11152227A (en)
AU (1) AU731176B2 (en)
CA (1) CA2214895C (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6555135B1 (en) 1999-04-27 2003-04-29 Bernard Charles Sherman Pharmaceutical compositions comprising co-micronized fenofibrate
WO2008104846A2 (en) * 2007-02-26 2008-09-04 Wockhardt Research Centre Pharmaceutical compositions of fenofibrate
US9180110B2 (en) 2007-02-26 2015-11-10 Wockhardt Ltd. Pharmaceutical compositions of fenofibrate

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2758459B1 (en) * 1997-01-17 1999-05-07 Pharma Pass FENOFIBRATE PHARMACEUTICAL COMPOSITION HAVING HIGH BIODAVAILABILITY AND PROCESS FOR PREPARING THE SAME
ID29270A (en) 1998-11-20 2001-08-16 Rtp Pharma Inc MICRO PARTICLES THAT ARE STABILIZED BY PHOSPHOLIPIDS THAT CAN SPREAD
US6982281B1 (en) 2000-11-17 2006-01-03 Lipocine Inc Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs
PT1235558E (en) * 1999-12-09 2006-09-29 Boots Co Plc THERAPEUTIC AGENTS
US6531158B1 (en) * 2000-08-09 2003-03-11 Impax Laboratories, Inc. Drug delivery system for enhanced bioavailability of hydrophobic active ingredients
US20080241070A1 (en) * 2000-09-21 2008-10-02 Elan Pharma International Ltd. Fenofibrate dosage forms
US20030224058A1 (en) * 2002-05-24 2003-12-04 Elan Pharma International, Ltd. Nanoparticulate fibrate formulations
US7276249B2 (en) * 2002-05-24 2007-10-02 Elan Pharma International, Ltd. Nanoparticulate fibrate formulations
FR2819720B1 (en) 2001-01-22 2004-03-12 Fournier Lab Sa NEW FENOFIBRATE TABLETS
JPWO2002069957A1 (en) 2001-03-01 2004-07-02 グレラン製薬株式会社 Fenofibrate-containing composition
US7056906B2 (en) 2001-09-21 2006-06-06 Schering Corporation Combinations of hormone replacement therapy composition(s) and sterol absorption inhibitor(s) and treatments for vascular conditions in post-menopausal women
US20070264348A1 (en) * 2002-05-24 2007-11-15 Elan Pharma International, Ltd. Nanoparticulate fibrate formulations
DE602004018617D1 (en) 2003-03-07 2009-02-05 Schering Corp SUBSTITUTED AZETIDINONE DERIVATIVES, THEIR PHARMACEUTICAL FORMULATIONS AND THEIR USE FOR THE TREATMENT OF HYPERCHOLESTEROLMIA
JP5137228B2 (en) 2003-03-07 2013-02-06 メルク・シャープ・アンド・ドーム・コーポレーション Substituted azetidinone compounds, substituted azetidinone formulations and their use for the treatment of hypercholesterolemia
US20080031825A1 (en) * 2004-08-20 2008-02-07 Yisheng Chen Pharmaceutical Compositions Comprising Effervescent Agents And Fenofibrate
EP1690528A1 (en) * 2005-02-11 2006-08-16 Abbott GmbH & Co. KG Process for the preparation of dosage forms comprising a solid dispersion of a microcrystalline active agent
KR101569227B1 (en) * 2008-03-11 2015-11-13 아스카 세이야쿠 가부시키가이샤 Solid dispersion, pharmaceutical compositions containing the same, and processes for the production of both
US11304960B2 (en) 2009-01-08 2022-04-19 Chandrashekar Giliyar Steroidal compositions
US9034858B2 (en) 2010-11-30 2015-05-19 Lipocine Inc. High-strength testosterone undecanoate compositions
US20180153904A1 (en) 2010-11-30 2018-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US9358241B2 (en) 2010-11-30 2016-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US20120148675A1 (en) 2010-12-10 2012-06-14 Basawaraj Chickmath Testosterone undecanoate compositions
US9498485B2 (en) 2014-08-28 2016-11-22 Lipocine Inc. Bioavailable solid state (17-β)-hydroxy-4-androsten-3-one esters
WO2016033549A2 (en) 2014-08-28 2016-03-03 Lipocine Inc. (17-ß)-3-OXOANDROST-4-EN-17-YL TRIDECANOATE COMPOSITIONS AND METHODS OF THEIR PREPARATION AND USE
JP2020503269A (en) 2016-11-28 2020-01-30 リポカイン インコーポレーテッド Oral testosterone undecanoate therapy

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4879301A (en) * 1987-04-28 1989-11-07 Hoei Pharmaceutical Co., Ltd. Antiallergic and antiinflammatory benzothiazolinone derivatives
FR2627696B1 (en) * 1988-02-26 1991-09-13 Fournier Innovation Synergie NEW GALENIC FORM OF FENOFIBRATE
US5190970A (en) * 1990-10-19 1993-03-02 E. R. Squibb & Sons, Inc. Method for preventing onset of or treating Type II diabetes employing a cholesterol lowering drug alone or in combination with an ace inhibitor
DK0617612T3 (en) * 1991-12-18 1998-04-14 Warner Lambert Co Process for preparing a solid dispersion
DE4418837A1 (en) * 1994-05-30 1995-12-07 Bayer Ag Thermal granulation process
FR2722984B1 (en) * 1994-07-26 1996-10-18 Effik Lab PROCESS FOR THE PREPARATION OF DRY PHARMACEUTICAL FORMS AND THE PHARMACEUTICAL COMPOSITIONS THUS PRODUCED
US5948438A (en) * 1995-01-09 1999-09-07 Edward Mendell Co., Inc. Pharmaceutical formulations having improved disintegration and/or absorptivity
US5545628A (en) * 1995-01-10 1996-08-13 Galephar P.R. Inc. Pharmaceutical composition containing fenofibrate
DE19504832A1 (en) * 1995-02-14 1996-08-22 Basf Ag Solid drug preparations
DE19509806A1 (en) * 1995-03-21 1996-09-26 Basf Ag Storage stable dosage forms
NZ286451A (en) * 1996-04-24 1998-04-27 Bernard Charles Sherman Controlled release pharmaceutical composition containing granules comprising drug, water-insoluble polymer and meltable carrier
US5883109A (en) * 1996-07-24 1999-03-16 Bristol-Myers Squibb Company Method for lowering serum lipid levels employing an MTP inhibitor in combination with another cholesterol lowering drug
US6018033A (en) * 1997-05-13 2000-01-25 Purdue Research Foundation Hydrophilic, hydrophobic, and thermoreversible saccharide gels and forms, and methods for producing same

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6555135B1 (en) 1999-04-27 2003-04-29 Bernard Charles Sherman Pharmaceutical compositions comprising co-micronized fenofibrate
WO2008104846A2 (en) * 2007-02-26 2008-09-04 Wockhardt Research Centre Pharmaceutical compositions of fenofibrate
WO2008104846A3 (en) * 2007-02-26 2009-04-02 Wockhardt Research Center Pharmaceutical compositions of fenofibrate
US8852635B2 (en) 2007-02-26 2014-10-07 Wockhardt Ltd Pharmaceutical compositions of fenofibrate
US9180110B2 (en) 2007-02-26 2015-11-10 Wockhardt Ltd. Pharmaceutical compositions of fenofibrate

Also Published As

Publication number Publication date
EP0904781A2 (en) 1999-03-31
JPH11152227A (en) 1999-06-08
CA2214895C (en) 1999-04-20
US20030031705A1 (en) 2003-02-13
EP0904781A3 (en) 1999-11-03
US6444225B1 (en) 2002-09-03
AU731176B2 (en) 2001-03-22
AU8607398A (en) 1999-04-15

Similar Documents

Publication Publication Date Title
CA2214895A1 (en) Improved pharmaceutical composition comprising fenofibrate
IE882921L (en) "new pharmaceutical preparation and process for its preparation"
AU2930797A (en) Novel antidiabetic compounds having hypolipidaemic, antihypertensive properties, process for their preparation and pharmaceutical compositions containing them
AU2793897A (en) Locally administrable, biodegradable and sustained-release pharmaceutical composition for periodontitis and process for preparation thereof
AU4048299A (en) Phenoxylpropanolamines, method for the production thereof and pharmaceutical compositions containing the same
HK1028769A1 (en) 2-aryl-8-oxodihydropurine derivatives, process for producing the same, medicinal compositions containing the same, and intermediates thereof
AU6362796A (en) Substituted 4-phenylaminothiazoles, their process for preparation and the pharmaceutical compositions containing them
IL119488A (en) Substituted 2, 4-imidazolidinediones, their production and pharmaceutical compositions containing them
HUP0001138A3 (en) Amino acids containing benzodioxane or benzoxazine, pharmaceutical compositions thereof and process for producing the same
AU3031797A (en) New substituted 2,4-thiazolidinedione derivatives, processes for producing them and pharmaceutical compositions containing them
CA2335551A1 (en) Thyroid hormone analogues and methods for their preparation
HUP9903459A3 (en) Oxa- and tiabicyclo[3.1.0]hexane-carboxylic acids, process for their preparation and pharmaceutical compositions of the same
HUP0100640A3 (en) Process for the preparation of 1,4-dihydropyridines
HUP0004588A3 (en) Substituted 1,2,3,4,5,6-hexahydro-2,6-methano-3-benzazocine-10-oles, method for the production and use thereof as medicaments and pharmaceutical compositions containing them
HUP9701660A3 (en) 10,13,15-trioxatricyclo[9.2.1.1.9.6]pentadekanon derivatives, process for producing them, and pharmaceutical compositions containing them
AU3011095A (en) 2,3-bridged 1,4-dihydropyridines, processes for their preparation and their use as medicaments
AU7552098A (en) Physiologically active substances tkr2449, process for producing the same, and microorganism
AU5639694A (en) 6,7-dialkoxy-3,4-dihydroisoquinolin-8-ol, process for preparation thereof and process for preparation of 6,7-dialkoxy-1,2,3,4-tetrahydroisoquinolin-8-ol using the compound
AU4729396A (en) Process for the preparation of 1,2-benzisothiazolin-3-ones
AU7705196A (en) Pesticide compounds, compositions and process for the preparation thereof
HU9800369D0 (en) Pellet-based pharmaceutical composition of controlled release with high content of potassium-chloride, and process for it's production
AU4845196A (en) 2-sulfinylnicotinamide derivatives, intermediate thereof, process for producing 2-sulfinylnicotinamide derivatives, and medicinal composition containing the same as active ingredient
HU9900263D0 (en) 11-acetyl-12,13-dioxabicyclo[8.2.1.]tridecenon derivatives, process for producing them and pharmaceutical compositions containing them
AU7773900A (en) Novel c13-substituted estra-1,3,5(10)-triene-3-yl-sulfamates, a method for producing the same and pharmaceutical compositions containing these compounds
AU1621199A (en) Manufacture of 1,3-propanediol esters

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed